GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Aims: The purpose of this study is to compare a combination of radiation therapy and weekly treatment of the chemotherapy drug cisplatin to the standard treatment for this type of cancer which is radiation therapy alone. This study will also evaluate the side effects of combining radiation therapy and chemotherapy with cisplatin. 
Diagnosis: Recurrent Endometrial Cancer 
Principal Investigator: Jean Hurteau, MD 
IRB Approval Number: EH09-122
Sponsor: Gynecologic Oncology Group (GOG) 
Contact: Interested patients should contact study nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes 

MD Anderson 2013-0340: Prophylactic Salpingectomy with Delayed Oophorecomy, Risk-Reducing Salpingo-Oophorectomy, and Ovarian Cancer Screening Among BRCA Mutation Carriers: A Proof-of-Concept Study
Aims: The goal of this clinical research study is to compare ovarian cancer screening, risk-reducing salpingo-oophorectomy (RRSO), and prophylactic salpingectomy with delayed oophorecctomy (PSDO). The safety of RRSO and PSDO will also be studied. This is an investigational study. At this time, the only known method that may lower your risk of ovarian cancer is to have both your ovaries and fallopian tubes removed (RRSO). Screening for ovarian cancer does not lower the risk that you will develop cancer. PSDO has not previously been studied and may not lower your ovarian cancer risk. PSDO is currently being used for research purposes only.
Diagnosis: Ovarian Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH14-387
Sponsor: The University of Texas MD Anderson Cancer Center/NCI
Contact: Interested patients should contact study nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UC13-1323: NCI 9322: A Phase 2 Study of XL184 (Carbozantinib) in Recurrent or Metastatic Endometrial CancerAims: The main purpose of this study is to find out what effects, good and/or bad, the study drug, XL184 (also called cabozantinib), has on you and your cancer. XL184 works by blocking proteins that allow tumors to grow. MET is a protein involved in tumor cell growth; VEGFR (vascular endothelial growth factor receptor) is a protein involved in the growth of new blood vessels in tumors. XL184 is designed to block these proteins and thereby inhibit tumor growth. This is a Phase 2 research study. This type of study is designed to see if the study drug might be effective in treating your cancer. In this study, only a relatively small number of people will receive the study drug. It is not known at this time whether XL184 will be helpful in fighting your cancer. This study will look at both the good and the bad effects of XL184
Diagnosis: Metastatic Endometrial Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH14-335
Sponsor: University of Chicago
Contact: Interested patients should contact study nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

GOG 0274: The OUTBACK Trial: A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Aims: The purpose of this study is to compare standard treatment; radiation therapy combined with the chemotherapy drug cisplatin (called chemo-radiation), to standard treatment plus additional investigational chemotherapy with the FDA approved agents, carboplatin and paclitaxel. The study will see if the addition of these chemotherapy agents will reduces the risk of tumor recurrence and improves overall survival. 
Diagnosis: Advanced Cervical Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-455
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

GOG 0277: A Phase III Randomized Trial of Gemcitabine (NSC #613327) plus Docetaxel (NSC #628503) followed by Doxorubicin (NSC # 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Aims: In this study, we are looking to see if giving chemotherapy with gemcitabine plus docetaxel, followed by doxorubicin, to patients whose leiomyosarcoma was found only in the uterus, decreases the chance that the leiomyosarcoma will come back (recur).
Diagnosis: Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-299
Sponsor: Gynecologic Oncology Group (GOG)  
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measureable Stage II or IVA, Stage IVB, or Recurrent Endometrial Cancer
Aims: The purpose of this study is to find out if the drug combination paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating your type of cancer and to find out what side effects are caused by treatment with these drugs.
Diagnosis: Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH14-321
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

× Alternate Text